Legislators
Bills
Statements
Lobbying
Travel
Searching...- Lobbying
- Lobbying by Karyopharm Therapeutics Inc.,
Lobbying Relationship
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
| Lobbyist | Covered positions? |
|---|---|
| Dave Boyer | Sp Ast Pres LA, Ast Com Leg, FDA; Sp Ast Sec HHS, Con Asst, Off of WH Liaison DoD; Con Asst, Off of Sec Lab See prior filing |
| John Stone | Counsel, House E&C Cmte, Oversight Subcommittee; Senior Counsel, House E&C Ctme Health Subcommittee See prior filing |
| Robb Walton | Senior Health Policy Advisor and Counsel Sen Cassidy; Advisor Rep. Cassidy; Healthcare Aide Sen. Enzi See prior filing |
| Brent Del Monte | Leg. Dir. Rep. Bliley; Sen. Counsel House Energy & Commerce Committee See prior filing |
| Remy Brim | Senior FDA Policy Advisor to the Senate HELP Committee Ranking Member, Sen. Patty Murray; Senior Health Policy Advisor Sen. Elizabeth Warren See prior filing |
| Matthew Hoffmann | See prior filing |
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
Termination
Q3 Report
Q2 Report
Q1 Report
Q4 Report
Registration
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate